BACKGROUND: Local ablative therapies, a partial-gland treatment for localized prostate cancer (PCa), offers targeted cancer treatment while minimizing side-effects. We aim to describe national-level patterns in its use for localized PCa in the United States (U.S.).METHODS:We retrospectively interrogated the hospital-based National Cancer Database (NCDB) for men with clinically localized PCa from 2010-2017. The main outcome was receipt of local tumor ablation with either cryo or laser-ablation, and other focal therapy including high-intensity focused ultrasound (HIFU). Patient level, hospital level, and demographic variables were collected. A mixed effects logistic regression analysis was utilized to identify covariates and predictors on the patient- and hospital-level. RESULTS: Overall, 11 278 patients received ablative therapy. Cryotherapy was performed in 8 883 (78.8%), laser ablation in 1 755 (15.6%), and other focal therapy (HIFU) in 640 (5.7%) cases. On the patient-level, intermediate-risk PCa patients were more likely to be treated with ablative therapy (OR 1.05, 95% CI 1.00 – 1.11, p=0.05) than low-risk PCa patients, as were men with Charlson Comorbidity Index >1 (OR 1.36, 95%CI 1.29 -1.43, p<0.01), men between 71-80 years (OR 3.70, 95%CI 3.43-3.99, p<0.01), men with Medicare insurance (OR 1.38, 95% 1.31-1.46, p<0.01), and an income <$47 999 (OR 1.16, 95% 1.06-1.21, p<0.01). On the hospital-level, local ablative therapy was less likely to be performed in academic/research facilities (OR 0.45, 95% CI 0.32-0.64, p<0.01), while hospitals with a high annual caseload were more likely to perform local ablative therapies (2nd quartile, OR 1.23, 95% CI 1.12-1.35, p<0.01). CONCLUSIONS: In this study, we report trends from 2010-2017, in utilization of local ablative therapies using a large national database of U.S. cancer centers. The technique is more commonly used in older men with comorbidities. The financial aspects of ablative therapy need to be addressed to avoid inequity in access to care.